Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

ACE2 glycans preferentially interact with the RBD of SARS-CoV-2 over SARS-CoV

Atanu Acharya, Diane L. Lynch, Anna Pavlova, Yui Tik Pang, James C. Gumbart
doi: https://doi.org/10.1101/2021.04.29.442038
Atanu Acharya
1School of Physics, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane L. Lynch
1School of Physics, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Pavlova
1School of Physics, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yui Tik Pang
1School of Physics, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. Gumbart
1School of Physics, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gumbart@physics.gatech.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

ABSTRACT

We report a distinct difference in the interactions of the glycans of the host-cell receptor, ACE2, with SARS-CoV-2 and SARS-CoV S-protein receptor-binding domains (RBDs). Our analysis demonstrates that the ACE2 glycan at N90 may offer protection against infections of both coronaviruses, while the ACE2 glycan at N322 enhances interactions with the SARS-CoV-2 RBD. The interactions of the ACE2 glycan at N322 with SARS-CoV RBD are blocked by the presence of the RBD glycan at N357 of the SARS-CoV RBD. The absence of this glycosylation site on SARS-CoV-2 RBD may enhance its binding with ACE2.

Competing Interest Statement

The authors have declared no competing interest.

Footnotes

  • ↵* aacharya42{at}gatech.edu

  • ↵* gumbart{at}physics.gatech.edu

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 03, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
ACE2 glycans preferentially interact with the RBD of SARS-CoV-2 over SARS-CoV
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
ACE2 glycans preferentially interact with the RBD of SARS-CoV-2 over SARS-CoV
Atanu Acharya, Diane L. Lynch, Anna Pavlova, Yui Tik Pang, James C. Gumbart
bioRxiv 2021.04.29.442038; doi: https://doi.org/10.1101/2021.04.29.442038
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
ACE2 glycans preferentially interact with the RBD of SARS-CoV-2 over SARS-CoV
Atanu Acharya, Diane L. Lynch, Anna Pavlova, Yui Tik Pang, James C. Gumbart
bioRxiv 2021.04.29.442038; doi: https://doi.org/10.1101/2021.04.29.442038

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Biophysics
Subject Areas
All Articles
  • Animal Behavior and Cognition (4685)
  • Biochemistry (10362)
  • Bioengineering (7682)
  • Bioinformatics (26343)
  • Biophysics (13534)
  • Cancer Biology (10694)
  • Cell Biology (15446)
  • Clinical Trials (138)
  • Developmental Biology (8501)
  • Ecology (12824)
  • Epidemiology (2067)
  • Evolutionary Biology (16867)
  • Genetics (11402)
  • Genomics (15484)
  • Immunology (10621)
  • Microbiology (25226)
  • Molecular Biology (10225)
  • Neuroscience (54483)
  • Paleontology (402)
  • Pathology (1669)
  • Pharmacology and Toxicology (2897)
  • Physiology (4345)
  • Plant Biology (9254)
  • Scientific Communication and Education (1587)
  • Synthetic Biology (2558)
  • Systems Biology (6781)
  • Zoology (1466)